About HealthLinx Limited (ASX:HTX)
-----------------------------------
HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are for diseases with high fatality:
?
Ovarian cancer diagnostic (OvPlex) targeting US$270m pa market
?
Prostate cancer targeting US$350m pa market
Current Scenario
----------------
Larger OvPlex? study confirms 93% diagnostic efficiency for ovarian cancer
Shares Outstanding : 148M
Is this .065c not very cheap?
Add to My Watchlist
What is My Watchlist?